The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients
Top Cited Papers
- 1 February 2014
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 63 (4), 321-328
- https://doi.org/10.1016/j.jacc.2013.07.104
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
- Boehringer Ingelheim
- Boehringer Ingelheim
- Boehringer Ingelheim
- AstraZeneca
- Bristol-Myers Squibb
- Schering-Plough
- GlaxoSmithKline
- Pfizer
- Merck & Co
This publication has 17 references indexed in Scilit:
- A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgeryThrombosis and Haemostasis, 2012
- Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trialJournal of Thrombosis and Haemostasis, 2011
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationCell Metabolism, 2011
- Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial FibrillationJournal of the American College of Cardiology, 2011
- Newly Identified Events in the RE-LY TrialNew England Journal of Medicine, 2010
- Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran EtexilateClinical Pharmacokinetics, 2008
- The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in HumansPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2007
- BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJournal of Thrombosis and Haemostasis, 2005
- A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialJournal of Thrombosis and Haemostasis, 2005
- A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip ReplacementNew England Journal of Medicine, 2001